Chlorophyllin
Phase 2Small molecule
Chlorophyllin is one of 17 small molecule programs targeting Necrosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
20 competitors in Necrosis
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Integrilin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Zoloft
VViatris Specialty LLC
Approved
Avastin
RochePhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Serplulimab
Shanghai Henlius BiotechPhase 2
QRX-3
EEbima Clifford Okundaye
Phase 3
Rocaltrol
Jazz PharmaceuticalsPreclinical
Actemra
CCelltrion
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Chlorophyllin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTata Memorial Centre